NYSE$ENOV

Enovis Corp · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Colfax's Q2 2021 earnings were announced, with increased full-year outlook and a strategic acquisition.

Colfax Corporation reported a strong second quarter in 2021, with a significant increase in net sales and adjusted EPS. The company's performance led to an increased full-year outlook and strategic acquisition of Mathys Bettlach AG.

  • Reported $0.19 EPS from continuing operations and $0.56 of adjusted EPS.
  • Raised FY 2021 adjusted EPS guidance range to $2.10-$2.20.
  • Signed agreement to acquire Mathys Bettlach AG to expand MedTech Reconstructive business outside of North America.
  • Made significant progress on separation into two independent public companies, targeting Q1 2022 completion.

Headline financials

Total Revenue

$986M

Previous: $620M+58.9%
EPS (adj)

$1.68

Previous: $0.27+522.2%
Capital Expenditures

$20.1M

Previous: -$50.4M+139.9%
Free Cash Flow

$58M

Previous: -$58.5M+199.2%
Net Income

$30M

Previous: -$8.05M+472.8%
Operating Income

$75.9M

Previous: -$4.92M+1643.2%
Gross Profit

$419M

Previous: $241M+73.8%
Cash & Equivalents

$62.3M

Previous: $66.4M-6.2%
Total Assets

$7.56B

Previous: $7.12B+6.1%
Stock-Based Comp

$9.46M

Previous: $8.56M+10.4%

Revenue & EPS history

Enovis · Revenue · Quarterly

$986M

Q2 2021+58.9%vs Q2 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Enovis · $131M total across 1 segment · Q2 2022

  • Reconstructive
    $131M

Forward guidance

Colfax raised its 2021 adjusted EPS outlook from $2.05-$2.15 to $2.10-$2.20 and its free cash flow outlook from $250 million or more to $275 million or more. For the third quarter of 2021, Colfax expects adjusted earnings of $0.50 to $0.55 per diluted share.

Tailwinds

  • Businesses continue to benefit from strengthening market demand and operating execution
  • ESAB business achieved strong growth and its highest-ever margins while successfully addressing raw material inflation
  • MedTech business continues to outperform peers in a market backdrop of improving demand
  • Reconstructive business saw 10% organic sales-per-day growth over 2019 levels
  • Acquisition announcement of Mathys to expand fast-growing MedTech Reconstructive business

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+1.6%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+0.1%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+21.3%

Q3 2011

Best reaction

-18.7%

Q1 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+9.7%+4.0%-4.5%
Q4 2025+13.8%+13.3%-2.2%
Q3 2025-9.7%+0.1%-14.2%
Q1 2025-2.9%+9.1%-7.2%
Q4 2024-4.9%-10.1%-10.3%
Q3 2024+10.6%+9.3%+10.0%
Q2 2024+4.0%+1.0%+3.5%
Q1 2024-7.5%-5.7%-9.3%
Q4 2023+4.3%+2.0%-0.1%
Q3 2023+4.0%+3.2%+8.8%
Q2 2023-5.6%-8.1%-10.0%
Q1 2023-1.8%-3.7%-3.9%
Q4 2022-9.6%-6.4%-18.9%
Q3 2022-3.4%+7.4%+15.9%
Q2 2022-3.7%-4.4%-17.5%
Q1 2022+5.7%+5.9%+7.4%
Q4 2021+0.9%+2.8%-3.7%
Q3 2021+0.4%-1.4%-14.9%
Q2 2021+3.6%+2.1%+8.5%
Q1 2021-1.1%-5.9%-3.2%
Q4 2020+13.7%+17.2%+16.8%
Q3 2020-4.1%+3.0%+30.8%
Q2 2020+6.8%+13.0%+8.1%
Q1 2020+14.6%+6.6%+33.4%
Q4 2019+2.8%-5.1%-55.3%
Q3 2019+9.6%+11.5%+6.0%
Q2 2019+7.9%+5.3%+15.1%
Q1 2019-5.5%-6.5%-4.7%
Q4 2018+5.3%+6.8%+15.0%
Q3 2018-0.3%+0.8%-12.5%
Q2 2018+5.5%+0.8%+12.9%
Q1 2018+2.2%+5.3%+1.1%
Q4 2017-8.5%-14.2%-11.2%
Q3 2017-12.7%-13.7%-14.0%
Q2 2017+1.1%+0.9%-4.3%
Q1 2017+1.9%+2.4%+7.4%
Q4 2016+2.2%-0.5%-5.0%
Q3 2016+7.8%+5.4%+26.9%
Q2 2016+0.0%-3.2%+3.4%
Q1 2016-18.7%
Q4 2015+18.9%
Q3 2015-6.5%
Q2 2015-5.1%
Q1 2015-0.8%
Q4 2014-0.9%
Q3 2014-5.1%
Q2 2014-6.9%
Q1 2014-3.4%
Q4 2013+7.0%
Q3 2013+0.0%
Q2 2013-0.1%
Q1 2013+4.5%
Q4 2012-5.8%
Q3 2012-2.7%
Q2 2012+5.2%
Q1 2011-5.7%
Q1 2012+1.3%
Q4 2011-1.9%
Q3 2011+21.3%
Q2 2011+16.2%
Q4 2010+16.2%
Q2 2010+16.2%
Q3 2010+1.0%
Q1 2010+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro